MajesTEC-3 Trial Results - Efficacy and Safety Profile of Teclistamab-Daratumumab

Dr. Nooka provides detailed analysis of the MajesTEC-3 trial, which randomized patients to receive teclistamab plus daratumumab versus standard control arms of daratumumab-dexamethasone or bortezomib-pomalidomide-dexamethasone. The primary endpoint demonstrated substantial progression-free survival improvement, with 83% of patients progression-free at 3 years in the experimental arm versus the expected 15 months in the control arm, yielding an impressive hazard ratio of 0.17 (83% reduction in progression/death risk).

Safety analysis reveals manageable toxicity profiles when comparing bispecific combinations to established controls. Immediate toxicities include cytokine release syndrome (CRS) risk with any bispecific antibody, but these are less severe than CAR-T related toxicities and resolve within 2-3 weeks of the first cycle. Hematological toxicities show slightly higher rates in the experimental arm, but grade 3-4 toxicities remain similar across both arms, providing reassurance compared to earlier single-arm trials that generated safety concerns.

A critical concern addressed was infection risk, given that both bispecific antibodies and CD38 antibodies carry infection potential. However, the study demonstrated no significant increase in infection rates compared to single-agent teclistamab trials, dispelling previous concerns about additive infection risk. Current supportive care measures including routine IVIG administration, low antibiotic thresholds, prompt drug holds during infections, and aggressive growth factor use have substantially reduced infection complications.

The impressive overall survival data shows 84% of patients alive at 3 years with a hazard ratio of 0.49, representing a 50% reduction in death risk in the early relapse setting, results exceeding expectations. The MajesTEC-9 trial in daratumumab-exposed patients reportedly achieved an even more impressive hazard ratio of 0.2, suggesting teclistamab's optimal role in early relapse rather than heavily pretreated settings where immune competency may be compromised.

Response rates and MRD negativity rates were unprecedented, with double the MRD negativity rates compared to standard care. The duration of response curve shows a flat line extending beyond 3 years, leading Dr. Nooka to speculate about potential cures, though he acknowledges this remains early speculation.